Abstract:NAT10 is highly expressed in BLCA patients and its abnormal level predicts bladder cancer progression and low overall survival rate. NAT10 is necessary and sufficient for BLCA tumorigenic properties. NAT10 is responsible for ac4C modification of target transcripts, including BCL9L, SOX4 and AKT1. NAT10 may serve as an effective and novel therapeutic target for BLCA. Background Dysregulation of the epitranscriptome causes abnormal expression of oncogenes in the tumorigenic process. Previous studies have shown that NAT10 can regulate mRNA translation efficiency through RNA acetylation. However, the role of NAT10‐mediated acetylation modification in bladder cancer remains elusive. Methods The clinical value of NAT10 was estimated according to NAT10 expression pattern based on TCGA data set and the tumor tissue array. Acetylated RNA immunoprecipitation sequencing was utilized to explore the role of NAT10 in mRNA ac4C modification. Translation efficiency and mRNA stability assay were applied to study the effect of NAT10‐deletion on target genes. The nude mouse model and genetically engineered mice were conducted to further verify the characteristics of NAT10 in promoting BLCA progression and regulating downstream targets. Results NAT10 was essential for the proliferation, migration, invasion, survival and the stem‐cell‐like properties of bladder cancer cell lines. NAT10 was responsible for mRNA ac4C modification in BLCA cells, including BCL9L, SOX4 and AKT1. Deficient NAT10 in both xenograft and transgenic mouse models of bladder cancer reduced the tumor burden. Furthermore, acetylated RNA immunoprecipitation sequencing data and RNA immunoprecipitation qPCR results revealed that NAT10 is responsible for a set of ac4C mRNA modifications in bladder cancer cells. Inhibition of NAT10 led to a loss of ac4C peaks in these transcripts and represses the mRNA's stability and protein expression. Mechanistically, the ac4C reduction modification in specific regions of mRNAs resulting from NAT10 downregulation impaired the translation efficiency of BCL9L, SOX4 and AKT1 as well as the stability of BCL9L, SOX4. Conclusions In summary, these findings provide new insights into the dynamic characteristics of mRNA's post‐transcriptional modification via NAT10‐dependent acetylation and predict a role for NAT10 as a therapeutic target in bladder cancer. Highlights NAT10 is highly expressed in BLCA patients and its abnormal level predicts bladder cancer progression and low overall survival rate. NAT10 is necessary and sufficient for BLCA tumourigenic properties. NAT10 is responsible for ac4C modification of target transcripts, including BCL9L, SOX4 and AKT1. NAT10 may serve as an effective and novel therapeutic target for BLCA.

Additional File 1 of Acetyltransferase NAT10 Regulates the Wnt/β-catenin Signaling Pathway to Promote Colorectal Cancer Progression Via Ac4c Acetylation of KIF23 Mrna

Acetyltransferase NAT10 regulates the Wnt/β-catenin signaling pathway to promote colorectal cancer progression via ac4C acetylation of KIF23 mRNA

Additional File 11 of the LINC00623/NAT10 Signaling Axis Promotes Pancreatic Cancer Progression by Remodeling Ac4c Modification of Mrna

Additional File 9 of CircCDKN2B-AS1 Interacts with IMP3 to Stabilize Hexokinase 2 Mrna and Facilitate Cervical Squamous Cell Carcinoma Aerobic Glycolysis Progression

Additional File 4 of the LINC00623/NAT10 Signaling Axis Promotes Pancreatic Cancer Progression by Remodeling Ac4c Modification of Mrna

Data Supplement from GSK-3β–Regulated N-Acetyltransferase 10 is Involved in Colorectal Cancer Invasion

NAT10 mediated mRNA acetylation modification patterns associated with colon cancer progression and microsatellite status

NAT10 Promotes Prostate Cancer Growth and Metastasis by Acetylating mRNAs of HMGA1 and KRT8

Retraction Note: the LINC00623/NAT10 Signaling Axis Promotes Pancreatic Cancer Progression by Remodeling Ac4c Modification of Mrna

NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1

NAT10 Promotes Prostate Cancer Growth and Metastasis by Acetylating mRNAs of HMGA1 and KRT8 (Adv. Sci. 32/2024)

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA

NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity

Lysine 2-hydroxyisobutyrylation of NAT10 promotes cancer metastasis in an ac4C-dependent manner

NAT10-mediated ac4C modification promotes stemness and chemoresistance of colon cancer by stabilizing NANOGP8

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

NAT10-mediated AXL mRNA N4-acetylcytidine modification promotes pancreatic carcinoma progression

High Expression of N-acetyltransferase 10: a Novel Independent Prognostic Marker of Worse Outcome in Patients with Hepatocellular Carcinoma.

NAT10‐mediated mRNA N4‐acetylcytidine modification promotes bladder cancer progression